J CLIN VIROL 润色咨询

JOURNAL OF CLINICAL VIROLOGY

出版年份：1998 年文章数：1097 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：4.8% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2023-11-27 ms3000001670439743 来自北京

    投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2022-07-01 ms3000001383664545

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向：新发病毒学
    经验分享：影响因子上去了，明显难中了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2021-12-29 衣谷

    如果文章发表了未提供ORCIDID如何添加？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2021-12-27 桑晒麦拉

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2018-06-10 香榭里

    HPV方面研究可以投这方面杂志吗?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2017-07-18 chenyuming

    3分边缘，希望能维持稳定，略有上升也不错。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2015-06-25 phoenix001

    IF一路下滑啊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2014-09-24 phoenix001

    已接收，此杂志较为严谨

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2014-07-05 phoenix001

    审稿速度:2.0
    经验分享：刚收到邮件，小修。评审人很专业、负责！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2171244, encodeId=70a521e12446a, content=投稿到接收一般需要多久啊，有没有最近接收的小伙伴可以分享一下啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59868163332, createdName=ms3000001670439743, createdTime=Mon Nov 27 11:40:04 CST 2023, time=2023-11-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1229996, encodeId=b67e122999660, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：新发病毒学<br>经验分享：影响因子上去了，明显难中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9ae8173215, createdName=ms3000001383664545, createdTime=Fri Jul 01 17:51:18 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092818, encodeId=09bb1092818d4, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092817, encodeId=330f109281e84, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557817, encodeId=430555e817e8, content=HPV方面研究可以投这方面杂志吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b11733948, createdName=香榭里, createdTime=Sun Jun 10 22:57:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539383, encodeId=792c53938345, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=512965, encodeId=0fcf512965e3, content=IF一路下滑啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=318, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Thu Jun 25 10:59:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=506278, encodeId=8e855062e80f, content=已接收，此杂志较为严谨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=345, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Wed Sep 24 19:38:00 CST 2014, time=2014-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=503937, encodeId=d46450393eed, content=审稿速度:2.0<br>经验分享：刚收到邮件，小修。评审人很专业、负责！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=361, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Sat Jul 05 06:13:00 CST 2014, time=2014-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=502850, encodeId=95c7502850ec, content=4.30投稿，到现在还是with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=321, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfbb90625, createdName=phoenix001, createdTime=Mon May 12 13:10:00 CST 2014, time=2014-05-12, status=1, ipAttribution=)]
    2014-05-12 phoenix001

    4.30投稿，到现在还是with editor

    0

共17条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分